<DOC>
	<DOCNO>NCT00561522</DOCNO>
	<brief_summary>The purpose study determine whether capecitabine effective prevent disease recurrence curative hepatic resection patient hepatocellular carcinoma .</brief_summary>
	<brief_title>Capecitabine Prevent Recurrence Hepatocellular Carcinoma After Curative Resection</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) account 70-90 % primary liver cancer , third common cause death cancer worldwide ; half million new case diagnose worldwide year . Hepatic resection establish one effective safe therapeutic option HCC . However , recurrence , particularly metastatic recurrence , one major obstacle long-term survival . Several adjuvant treatment use prevent recurrence surgery , effectiveness remain controversial . Fluorouracil ( FU ) , antimetabolite , commonly use chemotherapeutic agent , activity variety solid tumor include head neck , breast , prostate , pancreas , liver , genitourinary gastrointestinal tract . Capecitabine ( Xeloda ; Roche ) , novel prodrug 5-FU , orally administer tumor-selective cytotoxic agent convert 5-FU three enzyme . Capecitabine advantage convenient oral administration mimic effect protract intravenous ( i.v . ) 5-FU . Capecitabine currently approve FDA use first-line therapy patient metastatic colorectal cancer single-agent fluoropyrimidine therapy prefer . The drug also approve use single agent metastatic breast cancer patient resistant anthracycline- paclitaxel-based regimen anthracycline treatment contraindicate . Our previous study find PD-ECGF mRNA highly express human HCC particularly portal vein tumor thrombus compare noncancerous liver tissue . Capecitabine inhibit tumor growth metastatic recurrence resection HCC highly metastatic nude mouse model . The effect capecitabine may attribute high expression PD-ECGF tumor . The antitumor activity single-agent capecitabine modest patient HCC , include cirrhosis . Von Delius et al report capecitabine find safe treatment patient HCC , include compensate cirrhosis . On basis previous finding , design randomize , control trial test hypothesis adjuvant postoperative chemotherapy capecitabine prevent tumor recurrence radical hepatic resection patient HCC . Because capecitabine administer orally , consider treatment would clinically useful effectiveness could confirm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>First curative hepatic resection Hepatocellular Carcinoma ( histologically confirm ) Cirrhosis ChildPugh class A B A performance status ≤ 2 Adequate bone marrow , hepatic renal function ( white blood cell ( WBC ) count &gt; 2.5×10^3/μL , platelet count &gt; 40×10^3/μL , serum bilirubin level , alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) ≤ 2 time upper limit normal value , serum creatinine level &lt; 1.5 mg/dL ) Major organ ( heart , lung brain ) function normal An age 18 79 year . Any active infectious process Known hypersensitivity capecitabine The presence clinically confirm extrahepatic metastasis , macroscopic evidence tumor thrombus inferior vena cava main portal vein main bile duct Other previous synchronous malignant disorder Postoperative dysfunction organ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Recurrence</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Radical Hepatic Resection</keyword>
	<keyword>Drug Prevention</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Surgery</keyword>
</DOC>